Table 2.

Purinergic agonist potency for vasoconstriction or vasodilation according to vascular segment in rat lungs (20, 26, 27, 28)

	Potency	LPA		SPA		SPV		LPV
		E + a	E-	E +	E-	E +	E-	E +	E-
Vasoconstriction	Higher potency			α,β-meATP (20)	α,β-meATP (20)
			α,β-meATP [0.5 µM]b (20, 27) UTP (20)	UTP (20) ATP (20) 2-meSATP (20)	UDP (20) UTP (20) ATP (20) 2-meSATP (20)				α,β-meATP [0.1 µM] (27)
		UDP (20)	β,γ-meATP [2.8 µM] (27) UDP (20)	UDP (20)		ATPγ-S [2.5 µM] (28)
			2-meSATP [17.8 µM] (20, 27)			UTP [16,4 µM] (28) ATP [28.5 µM] (28)			2-meSATP [58.9 µM] (27) β,γ-meATP [95.4 µM] (27)
			ATP [169.8 µM] (20, 27)			ADP [117 µM] (28)			ATP [245.5 µM] (27)
		α,β-meATP (20) UDP (26) UTP (20, 26)		ADP (20)	ADP (20)
	Lower potency/no effect	ATP (20, 26) 2-meSATP (20) [ADP] (20)	[ADP] (20)
Vasodilation	Higher potency	2-meSATP [0.04 µM] (27)
		ATP [0.4 µM] (27) β,γ-meATP [0.9 µM] (27)
								2-meSATP [1.6 µM] (27)
		α,β-meATP [0.1 µM] (27)						ATP [16.6 µM] (27) β,γ-meATP [55.0 µM] (27)
	Lower potency/no effect	UTP (26) UDP (26)						α,β-meATP (27)

^aAbbreviations: E + presence of endothelium, E- absence of endothelium

^bEC₅₀ or EC₄₀ is shown in brackets when data was available